Suggested remit: To appraise the clinical and cost effectiveness of secukinumab within its marketing authorisation for treating enthesitis-related arthritis or juvenile psoriatic arthritis.
This topic is currently suspended whilst conversations between the company, NICE & NHS England are ongoing. A further update will be available in due course.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 3738
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 01 March 2023 | Suspended. This topic is currently suspended whilst conversations between the company, NICE & NHS England are ongoing. A further update will be available in due course. |
| 31 July 2020 - 28 August 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual